Overview

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Status:
Recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

Phase:

Phase 3

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborator:

Hoffmann-La Roche

Treatments:

Fulvestrant